Brown LC, Desai K, Kao C, et al. - Researchers performed this multicenter retrospective study to evaluate the outcomes of I+N (combination of ipilimumab & nivolumab) in mRCC patients (pts) with brain metastasis in a real-world setting. They recruited pts who received I+N for mRCC and brain metastases at the Duke Cancer Institute and Cleveland Clinic. This study included 17 pts with a median age of 60 (29% were female) who were treated with I+N. Among pts evaluable for response, the objective response rate was estimated to be 42%; with 29% attaining stable disease and 18% progressive disease as their best response. An immune-related adverse event occurred in 59% of pts. Disease progression was mainly responsible for treatment discontinuation. A PR was reported in 50% patients treated in the second-line or greater setting. Overall, findings revealed the clinical effectiveness of I+N in this real-world cohort of mRCC patients with brain metastasis.